Boyce et al. showed that treatment FD with denosumab, whose immunohistochemical staining on a pretreated bone biopsy specimen revealed marked RANKL expression, led to the dramatic reduction of bone destroy expansion and FD-related bone pain [19]. Here, TNFSF11 is linked to Fabry disease.